354 related articles for article (PubMed ID: 25275717)
1. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
2. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
4. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
5. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
7. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
8. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang I
Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827
[TBL] [Abstract][Full Text] [Related]
9. Update on pharmacotherapy for pulmonary hypertension.
Prior DL; Adams H; Williams TJ
Med J Aust; 2016 Sep; 205(6):271-6. PubMed ID: 27627939
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
Burger CD
Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561
[No Abstract] [Full Text] [Related]
11. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Jun; 12(6):960. PubMed ID: 26075562
[No Abstract] [Full Text] [Related]
12. Update on pulmonary arterial hypertension pharmacotherapy.
Velayati A; Valerio MG; Shen M; Tariq S; Lanier GM; Aronow WS
Postgrad Med; 2016 Jun; 128(5):460-73. PubMed ID: 27232660
[TBL] [Abstract][Full Text] [Related]
13. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
14. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
15. Pathways in pulmonary arterial hypertension: the future is here.
Sitbon O; Morrell N
Eur Respir Rev; 2012 Dec; 21(126):321-7. PubMed ID: 23204120
[TBL] [Abstract][Full Text] [Related]
16. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
17. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.
Zhang Y; Yu X; Jin Q; Luo Q; Zhao Z; Zhao Q; Yan L; Liu Z
Heart Fail Rev; 2019 Nov; 24(6):949-965. PubMed ID: 31044326
[TBL] [Abstract][Full Text] [Related]
19. Macitentan for the treatment of pulmonary arterial hypertension.
Spikes L; Williamson T; Satterwhite L
Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
[TBL] [Abstract][Full Text] [Related]
20. HIV-related pulmonary arterial hypertension: clinical presentation and management.
Sitbon O
AIDS; 2008 Sep; 22 Suppl 3():S55-62. PubMed ID: 18845923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
